{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    9,
    16,
    19,
    22,
    33,
    34,
    36,
    38
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_8",
        "affectedSection": "Section 5.1 - Overall Study Design and Plan",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Mandatory dose reduction for all subjects currently on 30 mg QD to 15 mg QD."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_8",
        "affectedSection": "Section 5.3.1.1 - Study Procedures",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Implementation of virtual visits, remote monitoring, and direct-to-patient drug shipment due to pandemic conditions."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_8",
        "affectedSection": "Section 6.1.7 - Toxicity Management",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated AST/ALT laboratory toxicity management guidelines and COVID-19 interruption rules."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_8",
        "reasonText": "The dose of 15 mg QD has been determined to be the optimal dose and is the proposed dose for marketing authorization globally.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_8",
        "reasonText": "To provide flexibility in conduct of study visits and procedures during state of emergency/pandemic times.",
        "category": "Operational",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_8",
        "reasonText": "To update study drug name to the appropriate generic name.",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_8",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.1",
        "beforeText": "Subjects will continue to receive upadacitinib 15 mg QD or upadacitinib 30 mg QD, respectively",
        "afterText": "Upon approval of protocol amendment 8, subjects receiving upadacitinib 30 mg QD will be switched to upadacitinib 15 mg QD at their next scheduled study visit.",
        "summary": "Global dose switch from 30mg to 15mg for all active subjects."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_8",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.0",
        "beforeText": "ABT-494",
        "afterText": "upadacitinib",
        "summary": "Updated investigational product name to generic name throughout protocol."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_8",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "5.3.1.1",
        "beforeText": "Not previously specified",
        "afterText": "subject visits may be conducted via phone or video conference and that vital signs and weight may be performed by the subject or caregiver as needed",
        "summary": "Added provisions for virtual study visits and remote assessments."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_8",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.4.1",
        "beforeText": "Not specified",
        "afterText": "acute, spontaneous perforation of the gastrointestinal tract that requires inpatient medical care or urgent surgical intervention",
        "summary": "Refined definition of gastrointestinal perforation for toxicity management."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_8",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1.7",
        "beforeText": "Previous AST/ALT guidelines",
        "afterText": "update AST/ALT laboratory toxicity management guidelines for ALT or AST > 8 Ã— ULN",
        "summary": "Updated threshold and management for hepatic lab abnormalities."
      }
    ],
    "summary": {
      "impactCount": 3,
      "reasonCount": 3,
      "changeCount": 5
    }
  }
}